Betazole

Summary

Betazole (CHEMBL1201323) is an approved small-molecule histamine agonist (ATC V04CG02).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V04CG02
• Chemistry: 111.15 Da · C5H9N3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201323
Name	Betazole
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	7741
ChEBI	CHEBI:59170
ATC	V04CG02
Molecular formula	C5H9N3
Molecular weight	111.15
InChIKey	JXDFEQONERDKSS-UHFFFAOYSA-N

SMILES: C1=C(NN=C1)CCN

IUPAC name: 2-(1H-pyrazol-5-yl)ethanamine

ChEBI definition: Pyrazole in which a hydrogen adjacent to one of the nitrogen atoms is substituted by a 2-aminoethyl group. It is a histamine H2-receptor agonist used clinically to test gastric secretory function.

Pharmacological roles (ChEBI): histamine agonist, diagnostic agent, gastrointestinal drug.

Also known as: Betazol, Betazole, SID11112911, BETAZOLE, betazole

Parent form; salt/anhydrous children: CHEMBL1200949, CHEMBL4303510

Patent coverage: 425 distinct patent families (1,588 SureChEMBL compound mentions), from 2 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Ubiquitin carboxyl-terminal hydrolase 2, Prelamin-A/C, Histamine H2 receptor.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HRH2	6.04	AC50	910	nM	CHEMBL_ACT_25169316
LMNA	5.95	Potency	1122	nM	CHEMBL_ACT_3664693
USP2	5.3	Potency	5012	nM	CHEMBL_ACT_4743936

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).